Ionis Pharmaceuticals reported highly statistically significant Phase III results for olezarsen in severe hypertriglyceridemia, showing up to 72% triglyceride reduction and 85% decrease in acute pancreatitis events. These results position olezarsen to address an unmet medical need. With plans to file an sNDA by year-end and launch in 2026, Ionis forecasts blockbuster potential, supported by the drug’s existing familial chylomicronemia indication.